CN100484543C - Medicament composition for treating hepatitis, prepartion method and use - Google Patents
Medicament composition for treating hepatitis, prepartion method and use Download PDFInfo
- Publication number
- CN100484543C CN100484543C CNB2004100815511A CN200410081551A CN100484543C CN 100484543 C CN100484543 C CN 100484543C CN B2004100815511 A CNB2004100815511 A CN B2004100815511A CN 200410081551 A CN200410081551 A CN 200410081551A CN 100484543 C CN100484543 C CN 100484543C
- Authority
- CN
- China
- Prior art keywords
- medicine
- injection
- acute
- extract
- chronic hepatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 167
- 238000000034 method Methods 0.000 title claims abstract description 25
- 208000006454 hepatitis Diseases 0.000 title claims description 50
- 239000000203 mixture Substances 0.000 title claims description 28
- 231100000283 hepatitis Toxicity 0.000 title description 14
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 68
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 68
- 239000007924 injection Substances 0.000 claims description 119
- 238000002347 injection Methods 0.000 claims description 119
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 113
- 238000002360 preparation method Methods 0.000 claims description 76
- 239000000284 extract Substances 0.000 claims description 74
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 52
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims description 26
- 239000000843 powder Substances 0.000 claims description 21
- 239000000706 filtrate Substances 0.000 claims description 20
- 206010008909 Chronic Hepatitis Diseases 0.000 claims description 19
- 238000005325 percolation Methods 0.000 claims description 19
- 230000001154 acute effect Effects 0.000 claims description 18
- 239000000463 material Substances 0.000 claims description 18
- 238000009472 formulation Methods 0.000 claims description 17
- 239000011347 resin Substances 0.000 claims description 16
- 229920005989 resin Polymers 0.000 claims description 16
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 claims description 15
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 claims description 15
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 claims description 15
- 230000006837 decompression Effects 0.000 claims description 15
- 238000004064 recycling Methods 0.000 claims description 15
- 238000010828 elution Methods 0.000 claims description 14
- 229960003371 protocatechualdehyde Drugs 0.000 claims description 14
- 150000002989 phenols Chemical class 0.000 claims description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 11
- 229910052799 carbon Inorganic materials 0.000 claims description 11
- 238000000605 extraction Methods 0.000 claims description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 10
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 claims description 10
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 claims description 10
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 claims description 10
- 238000010992 reflux Methods 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- 230000014759 maintenance of location Effects 0.000 claims description 9
- 239000000243 solution Substances 0.000 claims description 9
- 230000000274 adsorptive effect Effects 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 8
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 7
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 6
- -1 filters Substances 0.000 claims description 5
- 238000010253 intravenous injection Methods 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 230000000295 complement effect Effects 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 238000007639 printing Methods 0.000 claims description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- 235000019253 formic acid Nutrition 0.000 claims description 3
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- 239000003463 adsorbent Substances 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 229940126701 oral medication Drugs 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000003809 water extraction Methods 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- 230000008569 process Effects 0.000 abstract description 6
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 85
- 229940079593 drug Drugs 0.000 description 49
- 210000004369 blood Anatomy 0.000 description 45
- 239000008280 blood Substances 0.000 description 45
- 230000009467 reduction Effects 0.000 description 36
- 241001465754 Metazoa Species 0.000 description 32
- 206010067125 Liver injury Diseases 0.000 description 29
- 238000012360 testing method Methods 0.000 description 26
- 210000004185 liver Anatomy 0.000 description 23
- 241000700159 Rattus Species 0.000 description 21
- 210000003494 hepatocyte Anatomy 0.000 description 21
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 20
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 20
- 230000006378 damage Effects 0.000 description 18
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 16
- 238000000746 purification Methods 0.000 description 13
- 230000005856 abnormality Effects 0.000 description 12
- 239000006071 cream Substances 0.000 description 12
- 230000007850 degeneration Effects 0.000 description 12
- 230000003908 liver function Effects 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 231100000753 hepatic injury Toxicity 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 230000000630 rising effect Effects 0.000 description 9
- 229930182490 saponin Natural products 0.000 description 9
- 150000007949 saponins Chemical class 0.000 description 9
- 235000017709 saponins Nutrition 0.000 description 9
- 210000005229 liver cell Anatomy 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 241000282472 Canis lupus familiaris Species 0.000 description 7
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 7
- 230000002159 abnormal effect Effects 0.000 description 7
- 231100000439 acute liver injury Toxicity 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 231100001252 long-term toxicity Toxicity 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 239000012567 medical material Substances 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 230000037396 body weight Effects 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- 238000007689 inspection Methods 0.000 description 6
- 239000007928 intraperitoneal injection Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 210000001072 colon Anatomy 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 230000017074 necrotic cell death Effects 0.000 description 5
- 239000002547 new drug Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 230000001466 anti-adreneric effect Effects 0.000 description 4
- 239000003443 antiviral agent Substances 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 230000035568 catharsis Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 206010019692 hepatic necrosis Diseases 0.000 description 4
- 230000007866 hepatic necrosis Effects 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000004089 microcirculation Effects 0.000 description 4
- 230000003448 neutrophilic effect Effects 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 230000003285 pharmacodynamic effect Effects 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 239000013558 reference substance Substances 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 238000001694 spray drying Methods 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 206010002198 Anaphylactic reaction Diseases 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 206010023126 Jaundice Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000008087 TBil Methods 0.000 description 3
- 230000036783 anaphylactic response Effects 0.000 description 3
- 208000003455 anaphylaxis Diseases 0.000 description 3
- 230000002180 anti-stress Effects 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 238000007598 dipping method Methods 0.000 description 3
- 239000000890 drug combination Substances 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 231100000234 hepatic damage Toxicity 0.000 description 3
- 208000002672 hepatitis B Diseases 0.000 description 3
- 230000003118 histopathologic effect Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 239000002085 irritant Substances 0.000 description 3
- 231100000021 irritant Toxicity 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 230000008818 liver damage Effects 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 230000001926 lymphatic effect Effects 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 150000007965 phenolic acids Chemical class 0.000 description 3
- 235000009048 phenolic acids Nutrition 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- YUKQRDCYNOVPGJ-UHFFFAOYSA-N thioacetamide Chemical compound CC(N)=S YUKQRDCYNOVPGJ-UHFFFAOYSA-N 0.000 description 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 238000008715 DBil Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010020565 Hyperaemia Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000001638 cerebellum Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- SPPIIOPGDLITJE-VLQRKCJKSA-N diazanium;(2s,3s,4s,5r,6s)-6-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxylato-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-5-[(2r,3r,4s,5s,6s)-6-carboxy-3,4,5-trihydroxyoxan-2-yl]oxy-3,4-dihy Chemical compound N.N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O SPPIIOPGDLITJE-VLQRKCJKSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000000918 epididymis Anatomy 0.000 description 2
- 201000010063 epididymitis Diseases 0.000 description 2
- 238000010812 external standard method Methods 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 235000021472 generally recognized as safe Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 230000002443 hepatoprotective effect Effects 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 230000002584 immunomodulator Effects 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000000492 nasalseptum Anatomy 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 210000001328 optic nerve Anatomy 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 210000001562 sternum Anatomy 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- LTTQKYMNTNISSZ-MWTRTKDXSA-N (2S)-(-)-kurarinone Chemical compound C1([C@H]2OC=3C(C[C@@H](CC=C(C)C)C(C)=C)=C(O)C=C(C=3C(=O)C2)OC)=CC=C(O)C=C1O LTTQKYMNTNISSZ-MWTRTKDXSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 206010019727 Hepatitis acute Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010023129 Jaundice cholestatic Diseases 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 201000005267 Obstructive Jaundice Diseases 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- RMMPZDDLWLALLJ-UHFFFAOYSA-N Thermophillin Chemical compound COC1=CC(=O)C(OC)=CC1=O RMMPZDDLWLALLJ-UHFFFAOYSA-N 0.000 description 1
- 102000007501 Thymosin Human genes 0.000 description 1
- 108010046075 Thymosin Proteins 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000001989 choleretic effect Effects 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000008899 fufang danshen Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000009592 kidney function test Methods 0.000 description 1
- XQVFLLMCNGKXSM-UHFFFAOYSA-N kurarinone Natural products COc1cc(O)c(C(CC=C(C)C)C(=C)C)c2OC(CC(=O)c12)c3ccc(O)cc3O XQVFLLMCNGKXSM-UHFFFAOYSA-N 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000011206 morphological examination Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- KDADHLPROOOPIC-UHFFFAOYSA-N neokurarinol Natural products COc1cc(O)ccc1C1CC(=O)c2c(OC)cc(O)c(CC(CCC(C)(C)O)C(C)=C)c2O1 KDADHLPROOOPIC-UHFFFAOYSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- FPLYNRPOIZEADP-UHFFFAOYSA-N octylsilane Chemical group CCCCCCCC[SiH3] FPLYNRPOIZEADP-UHFFFAOYSA-N 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008807 pathological lesion Effects 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Substances OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 210000003314 quadriceps muscle Anatomy 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 244000132619 red sage Species 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000001373 regressive effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100815511A CN100484543C (en) | 2004-12-21 | 2004-12-21 | Medicament composition for treating hepatitis, prepartion method and use |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100815511A CN100484543C (en) | 2004-12-21 | 2004-12-21 | Medicament composition for treating hepatitis, prepartion method and use |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1795893A CN1795893A (en) | 2006-07-05 |
CN100484543C true CN100484543C (en) | 2009-05-06 |
Family
ID=36817348
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100815511A Active CN100484543C (en) | 2004-12-21 | 2004-12-21 | Medicament composition for treating hepatitis, prepartion method and use |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100484543C (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107441161A (en) * | 2017-06-19 | 2017-12-08 | 上海华源安徽锦辉制药有限公司 | A kind of preparation method of red sage roo drip liquid |
CN107260803A (en) * | 2017-06-19 | 2017-10-20 | 上海华源安徽锦辉制药有限公司 | The preparation method of Sodium Danshensu content in a kind of raising red sage roo drip liquid |
EP4193996A1 (en) * | 2021-12-11 | 2023-06-14 | Mendel University in Brno | Ginsenosides for treatment of chronic hepatitis b virus infections |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1089496A (en) * | 1993-01-06 | 1994-07-20 | 山东烟台西苑制药厂 | Compound sodium alginati diesteras |
CN1415303A (en) * | 2002-10-24 | 2003-05-07 | 成都浦泓生物科技开发有限公司 | Red sage root and Tienchi sustained release medication, its preparation method and medicinal application in vascular dementia |
CN1425379A (en) * | 2002-12-19 | 2003-06-25 | 上海博泰医药科技有限公司 | Traditional Chinese medicine active part compound preparation for curing cardiac and cerebral vascular diseases and its preparing method |
CN1456187A (en) * | 2002-05-10 | 2003-11-19 | 徐希平 | Use of red sage root and notoginseng in preparation of medicine for prevention of acute coronary syndrome |
CN1456188A (en) * | 2002-05-10 | 2003-11-19 | 徐希平 | Use of red rage root and notoginseng in preparation of medicine for prevention of cerebral apoplexy |
CN1470255A (en) * | 2002-07-22 | 2004-01-28 | 王智民 | Preparation extracted from the root of red-rooted solvia and pseudo-ginseng and its compound preparation and medical use |
CN1168496C (en) * | 2002-01-09 | 2004-09-29 | 中国药科大学 | Powder snuff of insulin for administration of lung and its preparing process |
-
2004
- 2004-12-21 CN CNB2004100815511A patent/CN100484543C/en active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1089496A (en) * | 1993-01-06 | 1994-07-20 | 山东烟台西苑制药厂 | Compound sodium alginati diesteras |
CN1168496C (en) * | 2002-01-09 | 2004-09-29 | 中国药科大学 | Powder snuff of insulin for administration of lung and its preparing process |
CN1456187A (en) * | 2002-05-10 | 2003-11-19 | 徐希平 | Use of red sage root and notoginseng in preparation of medicine for prevention of acute coronary syndrome |
CN1456188A (en) * | 2002-05-10 | 2003-11-19 | 徐希平 | Use of red rage root and notoginseng in preparation of medicine for prevention of cerebral apoplexy |
CN1470255A (en) * | 2002-07-22 | 2004-01-28 | 王智民 | Preparation extracted from the root of red-rooted solvia and pseudo-ginseng and its compound preparation and medical use |
CN1415303A (en) * | 2002-10-24 | 2003-05-07 | 成都浦泓生物科技开发有限公司 | Red sage root and Tienchi sustained release medication, its preparation method and medicinal application in vascular dementia |
CN1425379A (en) * | 2002-12-19 | 2003-06-25 | 上海博泰医药科技有限公司 | Traditional Chinese medicine active part compound preparation for curing cardiac and cerebral vascular diseases and its preparing method |
Also Published As
Publication number | Publication date |
---|---|
CN1795893A (en) | 2006-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103301412A (en) | Traditional Chinese medicine composition for treating alcoholic liver | |
CN101390887A (en) | Medicine composition of Panax notoginseng saponins | |
CN1931233B (en) | Medicine composition of red sage and epimedium for treating cardiac and cerebral vascular diseases | |
CN100484543C (en) | Medicament composition for treating hepatitis, prepartion method and use | |
CN101744986B (en) | Extraction method for ginseng, ophiopogon root and schisandra chinensis and preparation thereof | |
CN103432420B (en) | A kind of Chinese medicine composition for the treatment of diabetes and preparation method thereof and detection method | |
CN105250989A (en) | Donkey-hide glue small peptide composition for resisting fatigue | |
CN100528186C (en) | Process for preparing Chinese medicine compound injection for treating chronic renal failure and use | |
CN103690768A (en) | Creeping liriope-figwort-milkvetch root soft capsules and preparation method thereof | |
CN1923229B (en) | Pharmaceutical composition comprising notoginseng extract, Danshen extract and puerarin | |
CN1923228B (en) | Pharmaceutical composition comprising notoginseng extract, Danshen extract and ligustrazine | |
CN103933386B (en) | Compound hemophiliac capsule used for treating hemophilia and preparation method thereof | |
CN106581236A (en) | Medicinal composition for promoting gastric motility, and preparation method and application thereof | |
CN101745017B (en) | Method for extracting ginseng, dwarf lilyturf tuber and schisandra chinensis and preparation thereof | |
CN101745016B (en) | Extraction method of 'ginseng/radix ophiopogonis and schisandra chinensis' and preparation thereof | |
CN104257755A (en) | Composition with effect of treating diabetes as well as preparation method and application of composition | |
CN107669941A (en) | A kind of Chinese medicinal preparation method for improving insulin resistance | |
CN115400175B (en) | Traditional Chinese medicine composition for treating chronic renal failure | |
CN107469014A (en) | A kind of pharmaceutical composition for treating female mammary gland proliferation disease and preparation method thereof | |
CN116942771B (en) | Traditional Chinese medicine composition for treating coronary heart disease and application thereof | |
CN115957274B (en) | Traditional Chinese medicine composition for treating diabetes, blood circulation activating and vein relaxing gel composition and preparation method | |
CN101744989B (en) | Method for extracting schisandra chinensis, ginseng and dwarf lilyturf root and preparation thereof | |
CN101745006B (en) | Extraction method of ophiopogon root, ginseng and shiandra and preparation thereof | |
CN101744987B (en) | Single extraction method of ginseng, ophiopogon root and shiandra and preparation thereof | |
CN101745010B (en) | Extraction method of ginseng, ophiopogon root and shiandra and preparation thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: CHENGDU DIKANG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: DIKANG SCIENCE AND TECHNOLOGY PHARMACEUTICAL CO., LTD., SICHUAN PROV. Effective date: 20150506 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 610041 CHENGDU, SICHUAN PROVINCE TO: 611731 CHENGDU, SICHUAN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20150506 Address after: 611731 Sichuan city of Chengdu province high tech Zone (West) No. 1 Dixon Road Patentee after: Chengdu Dikang Pharmaceutical Co., Ltd. Address before: 610041 No. four, No. two, South Ring Road, Chengdu, Sichuan, 11 Patentee before: Dikang Science and Technology Pharmaceutical Co., Ltd., Sichuan Prov. |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 611731 Sichuan Chengdu high tech Zone (West District) di Kang Avenue No. 1 Patentee after: Chengdu Dikang pharmaceutical Limited by Share Ltd Address before: 611731 Sichuan Chengdu high tech Zone (West District) 1 Patentee before: Chengdu Dikang Pharmaceutical Co., Ltd. |
|
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20060705 Assignee: YAAN XUNKANG MEDICINE Co.,Ltd. Assignor: Chengdu Di Kang medicine companies LLC Contract record no.: X2021510000036 Denomination of invention: The invention relates to a pharmaceutical composition for treating hepatitis and a preparation method and application thereof Granted publication date: 20090506 License type: Common License Record date: 20210915 |
|
EE01 | Entry into force of recordation of patent licensing contract |